DNA קצב צמיחת רווח למניה בשנה הנוכחית Ginkgo Bioworks Holdings, Inc.

The technological barrier of Ginkgo Bioworks Holdings (DNA) has been weakened by a prolonged search for profitability. However, the Foundry computing environment generates network effects, making it difficult for clients to migrate to alternative solutions. Having become the "operating system" of synthetic biology, Ginkgo Bioworks Holdings (DNA) monetizes genetic code through royalties. The percentage deviation of EPS from last year's level demonstrates profit dynamics, where the metric value is 22.80.
פילוחים אנליטיים ודוחות נתונים של חברת Ginkgo Bioworks (DNA)

This indicator measures the growth rate of earnings per share compared to the same period last year, allowing for an assessment of the speed of the business's profitability recovery. By analyzing the year-over-year earnings per share trend, an investor can identify a critical gap between the ambitions of Ginkgo Bioworks Holdings (DNA) regarding cell programming and the actual capital burn amid falling demand.